CTTH Stock Overview
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CTT Pharmaceutical Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.03 |
| 52 Week High | US$0.10 |
| 52 Week Low | US$0.003 |
| Beta | 0 |
| 1 Month Change | 6.79% |
| 3 Month Change | -23.33% |
| 1 Year Change | 49.50% |
| 3 Year Change | -58.64% |
| 5 Year Change | -91.21% |
| Change since IPO | -92.88% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| CTTH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.3% | -1.5% | -3.2% |
| 1Y | 49.5% | 9.7% | 19.3% |
Return vs Industry: CTTH exceeded the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: CTTH exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| CTTH volatility | |
|---|---|
| CTTH Average Weekly Movement | 58.3% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CTTH's share price has been volatile over the past 3 months.
Volatility Over Time: CTTH's weekly volatility has decreased from 73% to 58% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Ryan Khouri | www.cttpharmaceuticals.com |
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company’s technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion.
CTT Pharmaceutical Holdings, Inc. Fundamentals Summary
| CTTH fundamental statistics | |
|---|---|
| Market cap | US$1.37m |
| Earnings (TTM) | -US$1.67m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs CTTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTTH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.67m |
| Earnings | -US$1.67m |
Last Reported Earnings
Sep 30, 2015
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CTTH perform over the long term?
See historical performance and comparison